Edwin A. Cohen
Founder, Chief Executive Officer and Co-Chairman
Prior to founding Summit, Mr. Cohen was the Founder, CEO and Chairman of Intranasal Therapeutics, Inc. and an original investor in ScinoPharm (Taiwan), after a successful career in the generic pharmaceutical industry. Most notably, he is founder and former Chairman and CEO of Barr Laboratories, Inc., a pharmaceutical company that traded on the NYSE and grew to over $3 billion in annual sales before its acquisition by Teva in 2008 for $7.5 billion. He also co-founded Davis Edwards Pharmacal Corporation, one of the first companies to manufacture and promote multisource drugs. He is a founding member of the Board of Directors of the Generic Pharmaceutical Industry Association, the predecessor to the Association for Accessible Medicines, and a founding member and Executive Board member of the National Association of Pharmaceutical Manufacturers. A graduate of Fordham University, Mr. Cohen received an Honorary Doctor of Science Degree and was appointed to the Board of Trustees of this institution.
Richard D. Cohen, J.D.
Mr. Cohen has over twenty-four years of diverse business and legal experience in finance, real estate investment, and business development. He is a Principal in Site Realty Group, a privately-held commercial real estate investment firm based in Maryland. He has been a board member of Summit since its founding and was also actively involved in Intranasal Therapeutics, Inc. He is a founding member of YLO, LLC, a venture fund providing seed capital to companies based in Maryland in the hospitality, restaurant, and agriculture industries. He started his career in New York as an attorney in the litigation department of Robinson Brog Leinwand Greene Genovese & Gluck PC. He earned a BA from Emory University and a JD with honors from the law school of the University of North Carolina at Chapel Hill.
Mr. Lomicka is Chairman of Coulter Ridge Capital and General Partner of The Yearling Fund. He has more than four decades of healthcare financial management and venture capital experience. Over the years, he has served as a director or senior executive of several healthcare companies, which were involved in health insurance, hospital management, medical devices, nursing/assisted living, and healthcare technology. As Senior Vice President of Finance for Humana, Inc., he planned, developed, and implemented financial strategies and controls, as the company grew from $145 million to $3 billion. Following Humana, he developed and managed healthcare investments for a venture capital firm in New York City. He also served as Secretary of Economic Development for the Commonwealth of Kentucky and later formed a venture capital firm in Louisville. He also founded an investment management firm. He earned his M.B.A. from the Wharton School at the University of Pennsylvania after completing his undergraduate degree from Wooster College.
R. Charles Moyer, Ph.D.
Dr. Moyer is Dean Emeritus of the College of Business and Professor of Finance and Entrepreneurship at the University of Louisville. Previously, he was Dean Emeritus of the Babcock Graduate School of Management at Wake Forest University, having served as Dean from 1996 until August 2003, and as the GMAC Insurance Chair of Finance from 1988 until 2005. Prior to joining the faculty at Wake Forest in 1988, he was Finance Department Chairman at Texas Tech University. He is the author of four textbooks in finance and economics and numerous journal articles. Dr. Moyer has been a member of the Board of Directors of Capitala Finance since May 2013. Dr. Moyer was a member of the Board of Directors of King Pharmaceuticals Inc. from 2000 through its acquisition by Pfizer in 2011. Dr. Moyer is also currently a director of the Enterprise Angels Community Fund I, and a member of the Advisory Board of USWorld Meds. He served as a member of the Kentucky and Southern Indiana Bridge Authority from 2010 - 2017, and currently serves on other community service boards. Dr. Moyer earned his BA in Economics and German from Howard University and his MBA and PhD (finance and economics) from the University of Pittsburgh.
Mr. Saunders is a General Partner of OCA Ventures and leads its healthcare investing activity. He represents OCA on the boards of mPulse, ReGroup Therapy and HealthiPass. He is also a Co-Founder and Chairman of XLerateHealth, a healthcare accelerator in Louisville, KY. Prior to OCA, Bob was a Senior Managing Director and General Partner at Chrysalis Ventures (Louisville) from 1997 to 2009 and served as a Senior Advisor to Chrysalis from 2009 to 2010. He was also co-founder of Saunders Murdock and Associates, a life science "super-angel" investor, and a Senior Managing Director at Providian Capital Management from 1993 to 1997. He began his career in consulting with Boston Consulting and Bain. Over the last 30 years, he has invested in many start-up companies and mentored many entrepreneurs. He received a BA from Stanford University, an M.Sc from the London School of Economics, and an MA from Harvard University. He is a Fulbright and a Marshall Scholar.